Presenting at a prestigious conference like AD/PD 2024 can significantly boost Vaxxinity's visibility in the biotech community and among investors. It underscores the company's commitment and progress in critical research areas, potentially leading to increased investor confidence and a positive impact on the stock price in the short term.